Key Dates

Related Announcements

RFA-AI-22-067 - International Centers of Excellence for Malaria Research (U19 Clinical Trial Not Allowed)

Issued by

National Institute of Allergy and Infectious Diseases (NIAID)

Purpose

The purpose of this Notice is to alert potential applicants of a clarification in the Eligibility section in RFA-AI-22-067 “International Centers of Excellence for Malaria Research (U19 Clinical Trial Not Allowed).”

Currently Reads:

Section III. Eligibility Information
3. Additional Information on Eligibility

Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application." This means that the NIH will not accept:

• • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Modified to read (changes in bold italics):

Section III. Eligibility Information
3. Additional Information on Eligibility

Number of Applications

Only one application per institution, normally identified by having a unique entity identifier (UEI) or NIH IPF number, is allowed.

The NIH will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application." This means that the NIH will not accept:

• • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

All other aspects of this Funding Opportunity Announcement remain the same.

Inquiries

Please direct all inquiries to:

Malla Rao, DrPH
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3352
Email: mrao@niaid.nih.gov